Stay updated on Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The displayed ClinicalTrials.gov site revision changed from v3.7.2 to v3.8.0; the page still shows a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T19:03:26.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    A site-wide NIH transition notice appears above the ClinicalTrials.gov 403 error page. The footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T20:42:38.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T20:48:50.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    A 403 Forbidden error page is now displayed, including a 403 header and a Home link, indicating restricted access to the study record rather than the usual ClinicalTrials.gov content. The new page presents an access-denied state rather than the study details.
    Difference
    0.5%
    Check dated 2026-09-29T20:46:10.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error where the study record content was shown. This indicates access to the content is blocked, representing a non-substantive access issue rather than a content update.
    Difference
    21%
    Check dated 2026-09-22T22:59:01.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The page's revision label changed from v3.6.6 to v3.7.0, indicating a refresh of the page metadata rather than a modification to study details.
    Difference
    0.1%
    Check dated 2026-09-15T21:36:40.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.